Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 52-57

  Smith, Vanessa ^a   Piette, Yves ^a   Van Praet, Jens T ^a   Decuman, Saskia ^a   Deschepper, Ellen ^a,b   Elewaut, Dirk ^a   De Keyser, Filip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

B lymphocytes; Diffuse systemic sclerosis; Rituximab

Indexed keywords

COLLAGEN; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLOOD CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERIAL BYPASS GRAFTING; DEPRESSION; DISEASE ACTIVITY SCORE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FINGER ULCER; FOLLOW UP; FUNCTIONAL STATUS; HEARTBURN; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNE DEFICIENCY; HYPERTENSION; HYPERVENTILATION; IMMUNOGLOBULIN DEFICIENCY; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; ORGAN; PILOT STUDY; PRIORITY JOURNAL; ROTATOR CLUFF TENDINITIS; SCORING SYSTEM; SEPSIS; SKIN INFECTION; STOMATITIS; SUBFERTILITY; SYSTEMIC SCLEROSIS; TENDINITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PILOT PROJECTS; SCLERODERMA, DIFFUSE; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 84871861496     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120778     Document Type: Article

References (25)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
2. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, et al. B cells in systemic sclerosis: A possible target for therapy. Autoimmun Rev 2011;10:624-30.
3. Fujimoto M, Sato S. B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746-51. (Pubitemid 41546494)
4. Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954-66. (Pubitemid 44411958)
5. Hitomi Y, Tsuchiya N, Hasegawa M, Fujimoto M, Takehara K, Tokunaga K, et al. Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. Tissue Antigens 2007;69:242-9. (Pubitemid 46696949)
6. Lafyatis R, O'Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-8. (Pubitemid 47502765)
7. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S. Elevated serum BAFF levels in patients with systemic sclerosis - Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201. (Pubitemid 43122202)
8. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-27. (Pubitemid 38725103)
9. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-43.
10. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunaga K, et al. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 2004;50:4002-7. (Pubitemid 39643949)
11. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-24. (Pubitemid 37271558)
12. McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008;47:552-3.
13. Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010;12:R54.
14. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study. Rheumatology 2010;49:271-80.
15. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009;60:578-83.
16. Smith VP, Van Praet JT, Vandooren BR, Vander Cruyssen B, Naeyaert JM, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study. Ann Rheum Dis 2010;69:193-7.
17. Daoussis D, Liossis SC, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012;Suppl 71:S17-22.
18. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35. (Pubitemid 34016202)
19. Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006;54:3655-60. (Pubitemid 44737178)
20. Van Praet JT, Smith V, Haspeslagh M, Degryse N, Elewaut D, De Keyser F. Histopathological cutaneous alterations in systemic sclerosis: A clinicopathological study. Arthritis Res Ther 2011;13:R35.
21. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65-70.
22. Domsic R, Medsger TJ. Disease subsets in clinical practice. In: Varga J, Denton C, Wigley F, editors. Scleroderma: From pathogenesis to comprehensive management. New York: Springer Science and Business Media LCC; 2012:45-52.
23. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. Outcome measurements in scleroderma: Results from a Delphi exercise. J Rheumatol 2007;34:501-9. (Pubitemid 46364004)
24. Clements PJ, Furst DE, Wong WK, Mayes M, White B, Wigley F, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis - Analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999;42:1194-203. (Pubitemid 29268956)
25. Altman RD, Medsger TA, Bloch DA, Michel BA. Predictors of survival in systemic-sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.